The WHO experts noted that baricitinib, a type of drug known as a Janus kinase (JAK) inhibitor, has similar effects to other arthritis drugs called interleukin-6 (IL-6) inhibitors.
The University of Washington’s own highly influential model projects that the number of daily reported cases in the US will crest at 1.2 million by Jan.